Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$7.23 +1.7%	$6.30	$3.93 ▼ $7.54	$370.74M	1.55	730,185 shs	850,820 shs
ALKS Alkermes	$29.75 +2.4%	$28.34	$25.56 ▼ $36.45	$4.91B	0.47	1.71 million shs	1.39 million shs
MEDP Medpace	$463.64 +2.3%	$378.86	$250.05 ▼ $501.30	$13.03B	1.42	403,145 shs	328,935 shs
OMCL Omnicell	$33.62 +5.4%	$29.62	$22.66 ▼ $55.74	$1.54B	0.78	641,752 shs	863,923 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+1.40%	+8.72%	+12.62%	+37.98%
ALKS Alkermes	0.00%	+2.41%	+12.14%	+1.36%	+5.27%
MEDP Medpace	0.00%	+1.26%	+1.75%	+57.22%	+17.17%
OMCL Omnicell	0.00%	+6.09%	+19.52%	+19.09%	-22.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.4271 of 5 stars	3.5	2.0	4.5	2.4	2.5	1.3
ALKS Alkermes	4.7287 of 5 stars	4.4	1.0	4.2	2.5	2.5	1.9
MEDP Medpace	4.3364 of 5 stars	2.0	3.0	4.6	3.5	4.2	1.3
OMCL Omnicell	2.9943 of 5 stars	3.3	3.0	0.0	2.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.50	169.71% Upside
ALKS Alkermes	2.83	Moderate Buy	$41.08	38.10% Upside
MEDP Medpace	1.93	Reduce	$406.60	-12.30% Downside
OMCL Omnicell	2.57	Moderate Buy	$46.71	38.95% Upside

Current Analyst Ratings Breakdown

Latest ALKS, ABEO, MEDP, and OMCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $20.00
8/11/2025	OMCL Omnicell	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $55.00
7/30/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$40.00 ➝ $42.00
7/29/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/29/2025	MEDP Medpace	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$300.00 ➝ $305.00
7/25/2025	MEDP Medpace	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$328.00 ➝ $510.00
7/23/2025	MEDP Medpace	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Sell
7/23/2025	MEDP Medpace	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/23/2025	MEDP Medpace	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$298.00 ➝ $436.00
7/23/2025	MEDP Medpace	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$270.00 ➝ $430.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	105.93	N/A	N/A	$1.01 per share	7.16
ALKS Alkermes	$1.56B	3.15	$2.65 per share	11.22	$9.05 per share	3.29
MEDP Medpace	$2.11B	6.18	$13.95 per share	33.23	$26.56 per share	17.46
OMCL Omnicell	$1.11B	1.39	$3.06 per share	10.98	$26.84 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	$0.70	10.33	N/A	N/A	N/A	89.05%	45.64%	N/A
ALKS Alkermes	$367.07M	$2.08	14.30	21.72	1.71	23.15%	24.86%	17.14%	10/23/2025 (Estimated)
MEDP Medpace	$404.39M	$13.45	34.47	33.94	2.92	18.74%	67.66%	21.86%	10/20/2025 (Estimated)
OMCL Omnicell	$12.53M	$0.50	67.24	27.11	9.81	2.01%	4.27%	2.44%	10/29/2025 (Estimated)

Latest ALKS, ABEO, MEDP, and OMCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	$1.71	+$2.10	$1.71	$21.71 million	$0.40 million
7/31/2025	Q2 2025	OMCL Omnicell	$0.30	$0.45	+$0.15	$0.12	$275.57 million	$290.56 million
7/29/2025	Q2 2025	ALKS Alkermes	$0.42	$0.52	+$0.10	$0.52	$343.20 million	$390.66 million
7/21/2025	Q2 2025	MEDP Medpace	$3.00	$3.10	+$0.10	$3.10	$537.70 million	$603.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
MEDP Medpace	N/A	N/A	N/A	N/A	N/A
OMCL Omnicell	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.09	6.73	6.65
ALKS Alkermes	N/A	3.23	2.85
MEDP Medpace	N/A	0.43	0.43
OMCL Omnicell	0.13	1.42	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ALKS Alkermes	95.21%
MEDP Medpace	77.98%
OMCL Omnicell	97.70%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	5.40%
ALKS Alkermes	4.40%
MEDP Medpace	20.30%
OMCL Omnicell	2.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.28 million	48.51 million	Optionable
ALKS Alkermes	1,800	165.08 million	157.82 million	Optionable
MEDP Medpace	5,900	28.09 million	22.39 million	Optionable
OMCL Omnicell	3,670	45.93 million	44.78 million	Optionable

ALKS, ABEO, MEDP, and OMCL Headlines

Recent News About These Companies

Algert Global LLC Has $2.73 Million Holdings in Omnicell, Inc. $OMCL

August 23 at 5:04 AM | marketbeat.com

Vanguard Group Inc. Boosts Holdings in Omnicell, Inc. $OMCL

August 22 at 3:18 AM | marketbeat.com

Fox Run Management L.L.C. Invests $448,000 in Omnicell, Inc. $OMCL

August 21 at 4:07 AM | marketbeat.com

Public Sector Pension Investment Board Boosts Stake in Omnicell, Inc. (NASDAQ:OMCL)

August 19, 2025 | marketbeat.com

Redmond Asset Management LLC Has $4.93 Million Stake in Omnicell, Inc. (NASDAQ:OMCL)

August 17, 2025 | marketbeat.com

Liontrust Investment Partners LLP Raises Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

August 17, 2025 | marketbeat.com

OMCL Q2 Deep Dive: Product Innovation and Recurring Revenue Drive Upbeat Guidance

August 14, 2025 | finance.yahoo.com

Piper Sandler Reiterates $55.00 Price Target for Omnicell (NASDAQ:OMCL)

August 14, 2025 | americanbankingnews.com

5 Must-Read Analyst Questions From Omnicell’s Q2 Earnings Call

August 13, 2025 | msn.com

Omnicell (NASDAQ:OMCL) Price Target Cut to $55.00 by Analysts at Piper Sandler

August 12, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Buys 24,301 Shares of Omnicell, Inc. (NASDAQ:OMCL)

August 12, 2025 | marketbeat.com

7OMCL : Analyst Expectations For Omnicell ...

August 11, 2025 | benzinga.com

Omnicell (NASDAQ:OMCL) Downgraded to "Buy" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

1 Small-Cap Stock for Long-Term Investors and 2 We Avoid

August 8, 2025 | finance.yahoo.com

Omnicell management to meet with KeyBanc

August 6, 2025 | msn.com

Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by XTX Topco Ltd

August 3, 2025 | marketbeat.com

Omnicell, Inc. (OMCL) Q2 2025 Earnings Conference Call Transcript

August 1, 2025 | seekingalpha.com

Omnicell, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 1, 2025 | seekingalpha.com

Omnicell (NASDAQ:OMCL) Shares Gap Up - Here's What Happened

August 1, 2025 | marketbeat.com

Omnicell (NASDAQ:OMCL) Issues Q3 2025 Earnings Guidance

August 1, 2025 | marketbeat.com

Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS, ABEO, MEDP, and OMCL Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$7.23 +0.12 (+1.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.21 -0.02 (-0.28%)

As of 08/22/2025 07:53 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Alkermes NASDAQ:ALKS

$29.75 +0.69 (+2.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$29.75 0.00 (0.00%)

As of 08/22/2025 05:17 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Medpace NASDAQ:MEDP

$463.64 +10.30 (+2.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$463.38 -0.26 (-0.06%)

As of 08/22/2025 07:57 PM Eastern

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Omnicell NASDAQ:OMCL

$33.62 +1.73 (+5.42%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$33.69 +0.07 (+0.20%)

As of 08/22/2025 05:52 PM Eastern

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time